- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04320186
Community Influences Transitions in Youth Health (CITY) Health II - Center for the Study of Community Health (CH-II)
April 7, 2023 updated by: Susan Davies, University of Alabama at Birmingham
Community Influences Transitions in Youth Health II - Center for the Study of Community Health
The purpose of this protocol is to develop and evaluate an HIV prevention Entertainment Education (EE) intervention aimed at reaching underserved, at-risk African Americans, aged 18-25 years, living in disadvantaged urban neighborhoods in the Birmingham area.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The goal of this 5 year project is to promote HIV testing and improve HIV-related risk behaviors (e.g.
condom use, substance use before sex, regular Sexually Transmitted Infection (STI) testing) via population-sensitive and population-specific HIV prevention videos that are appealing, evidence-based, scalable, and sustainable to the target population.
Formative research was conducted in Phase I (Year 1-2), to pre-test the questionnaire and gather in-depth data (via focus groups, intercept interviews, and individual structured interviews) to inform intervention development.
Phase 2 of the project involved developing, delivering, and subsequently evaluating the efficacy of peer-driven EE HIV prevention messaging to broader social networks via a social media platform, with the platform contingent on formative data.
An HIV education video series, "The Beat HIVe", was produced and served as intervention materials for the quasi-experimental research project.
Respondent Driven Sampling (RDS) was used to access and use the social networks of high-risk youths as channel and agents for change.
RDS is a recent innovative adaptation of chain-referral network sampling that provides peer-driven access to hard-to-reach subpopulations while reducing sampling biases associated with conventional snowball sampling.
Study Type
Interventional
Enrollment (Actual)
334
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294-0022
- University of Alabama at Birmingham
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 25 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
African American young adults Aged 18-25 Living in the Birmingham USA Competent to give informed consent
Exclusion Criteria:
Obvious psychosis, dementia, inability to hear. Plan to move within the next 6 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment
Participants viewed informational video content plus entertainment content
|
video
|
Placebo Comparator: Control
Participants viewed entertainment content only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HIV Knowledge Questionnaire-18
Time Frame: Baseline
|
This scale assess an individual level of HIV-related knowledge.
For each of the 18 true/false, HIV- related questions, a score of 1 was assigned to each 'correct' answer.
Assessments were based on the analysis of the summation of these scores, which had a possible range of 0 to 18, whereby higher scores indicated greater knowledge of HIV.
|
Baseline
|
HIV Knowledge Questionnaire-18
Time Frame: 3 months
|
This scale assess an individual level of HIV-related knowledge.
For each of the 18 true/false, HIV- related questions, a score of 1 was assigned to each 'correct' answer.
Assessments were based on the analysis of the summation of these scores, which had a possible range of 0 to 18, whereby higher scores indicated greater knowledge of HIV.
|
3 months
|
HIV Knowledge Questionnaire-18
Time Frame: 6 months
|
This scale assess an individual level of HIV-related knowledge.
For each of the 18 true/false, HIV- related questions, a score of 1 was assigned to each 'correct' answer.
Assessments were based on the analysis of the summation of these scores, which had a possible range of 0 to 18, whereby higher scores indicated greater knowledge of HIV.
|
6 months
|
Perceived HIV-related Stigma
Time Frame: Baseline
|
The scores are scaled in the positive direction implying that the higher the score, the higher the level of stigma.
The possible overall stigma score ranges from 40 to 160, low-level stigma is between 25th percentile and 50th percentile (40-80), middle-level stigma is between 50th percentile and 75th percentile (81-120), while high-level stigma is for values greater than 75th percentile (121-160).
|
Baseline
|
Perceived HIV-related Stigma
Time Frame: 3 months
|
The scores are scaled in the positive direction implying that the higher the score, the higher the level of stigma.
The possible overall stigma score ranges from 40 to 160, low-level stigma is between 25th percentile and 50th percentile (40-80), middle-level stigma is between 50th percentile and 75th percentile (81-120), while high-level stigma is for values greater than 75th percentile (121-160).
|
3 months
|
Perceived HIV-related Stigma
Time Frame: 6 months
|
The scores are scaled in the positive direction implying that the higher the score, the higher the level of stigma.
The possible overall stigma score ranges from 40 to 160, low-level stigma is between 25th percentile and 50th percentile (40-80), middle-level stigma is between 50th percentile and 75th percentile (81-120), while high-level stigma is for values greater than 75th percentile (121-160).
|
6 months
|
Condom Use Self-Efficacy Scale
Time Frame: Baseline, 3- and 6 months
|
This is a 28 item self-report questionnaire which elicits responses using a five-point Likert scale format, ranging from 'strongly disagree' to 'strongly agree'.
Each of the responses is scored as follows: 'strongly disagree' = 0, 'disagree' = 1, 'undecided' = 2, 'agree' = 3 and 'strongly agree' = 4.
After reversing for negatively worded items, scores are summed.
The possible range of scores is 0-112, with higher scores indicating greater condom use self-efficacy.
|
Baseline, 3- and 6 months
|
Condom Use Self-Efficacy Scale
Time Frame: Baseline
|
This is a 28 item self-report questionnaire which elicits responses using a five-point Likert scale format, ranging from 'strongly disagree' to 'strongly agree'.
Each of the responses is scored as follows: 'strongly disagree' = 0, 'disagree' = 1, 'undecided' = 2, 'agree' = 3 and 'strongly agree' = 4.
After reversing for negatively worded items, scores are summed.
The possible range of scores is 0-112, with higher scores indicating greater condom use self-efficacy.
|
Baseline
|
Condom Use Self-Efficacy Scale
Time Frame: 3 months
|
This is a 28 item self-report questionnaire which elicits responses using a five-point Likert scale format, ranging from 'strongly disagree' to 'strongly agree'.
Each of the responses is scored as follows: 'strongly disagree' = 0, 'disagree' = 1, 'undecided' = 2, 'agree' = 3 and 'strongly agree' = 4.
After reversing for negatively worded items, scores are summed.
The possible range of scores is 0-112, with higher scores indicating greater condom use self-efficacy.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Timeline Followback
Time Frame: 6 months
|
Assesses sexual activity over the previous 90-days.
The baseline assessment collected sexual risk behavior data for the 3 months prior to enrolling in the study; the 3-month data collection visit examined participant's sexual risk behavior in the 90 days since their baseline visit; and their 6-month data collection visit used TLFB to record sexual risk behavior since their last visit.
Following each interview, TLFB data are coded in accordance with a discrete coding algorithm that allows the research team to summarize all of this information directly on the daily blocks on the calendar.
|
6 months
|
HIV Testing Questionnaire
Time Frame: 6 months
|
HIV testing uptake-after initial education.
Participants were asked if they wanted to take a free and optional HIV test.
If the participant declined they were asked additional 6 questions about their reason for declining.
If they accepted the HIV test, they were asked additional 20 questions regarding how often they tested, knowledge of testing resources, sexual practices, and reason for accepting a test.
This questionnaire was developed by study staff and is not scored.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Susan L Davies, University of Alabama at Birmingham
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 3, 2015
Primary Completion (Actual)
June 1, 2019
Study Completion (Actual)
December 31, 2020
Study Registration Dates
First Submitted
March 6, 2020
First Submitted That Met QC Criteria
March 23, 2020
First Posted (Actual)
March 24, 2020
Study Record Updates
Last Update Posted (Actual)
April 10, 2023
Last Update Submitted That Met QC Criteria
April 7, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 150219009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Entertainment education
-
Northern Arizona UniversityWithdrawnEarly Childhood CariesUnited States
-
University of TurkuCity of HelsinkiRecruitingPsychotic DisorderFinland
-
University College, LondonUnknownSedentary Lifestyle | Appetite and General Nutritional DisordersUnited Kingdom
-
Yale UniversityEnrolling by invitation
-
National University of SingaporeNational Skin Centre, Singapore; Ministry of Health, SingaporeUnknownSexually Transmitted InfectionsSingapore
-
Erzincan UniversityCompletedQuality of Life | Nursing Caries | Breastfeeding | Postpartum | Nursing Model | Levine Conservation Model
-
Oregon Health and Science UniversityEnrolling by invitation
-
Mexican National Institute of Public HealthUniversity of North Carolina, Chapel Hill; Danone ResearchCompleted
-
University of Social Sciences and Humanities, WarsawNational Science Centre, PolandRecruiting